Literature DB >> 9502506

Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis.

F J Vasallo, P Martín-Rabadán, L Alcalá, J M García-Lechuz, M Rodríguez-Créixems, E Bouza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9502506     DOI： 10.1086/517087

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

1.  Is it time to change fluoroquinolone breakpoints for Salmonella spp.?

Authors:  Frank Møller Aarestrup; Camilla Wiuff; Kåre Mølbak; E John Threlfall
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

2.  New quinolone resistance phenomenon in Salmonella enterica: nalidixic acid-susceptible isolates with reduced fluoroquinolone susceptibility.

Authors:  Antti J Hakanen; Marianne Lindgren; Pentti Huovinen; Jari Jalava; Anja Siitonen; Pirkko Kotilainen
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Nalidixic acid-resistant strains of Salmonella showing decreased susceptibility to fluoroquinolones in the midwestern region of the Republic of Ireland due to mutations in the gyrA gene.

Authors:  Michael P Ryan; Colm Dillon; Catherine C Adley
Journal:  J Clin Microbiol       Date:  2011-03-09       Impact factor: 5.948

4.  Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.

Authors:  T Guillard; E Cambau; F Chau; L Massias; C de Champs; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

5.  Reply to Chu et al., "Adoption of the New CLSI Fluoroquinolone Breakpoints for Enterobacteriaceae".

Authors:  Tam T Van; Emi Minejima; Chiao An Chiu; Susan M Butler-Wu
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

6.  Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003.

Authors:  José M Marimón; María Gomáriz; Carmen Zigorraga; Gustavo Cilla; Emilio Pérez-Trallero
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia.

Authors:  A Hakanen; P Kotilainen; P Huovinen; H Helenius; A Siitonen
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

8.  Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium.

Authors:  Morten Helms; Pernille Vastrup; Peter Gerner-Smidt; Kåre Mølbak
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

9.  Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.

Authors:  J M Ling; E W Chan; A W Lam; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

10.  Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.

Authors:  Nicolas Allou; Emmanuelle Cambau; Laurent Massias; Françoise Chau; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.